In this study, we evaluated the efficacy and safety of adding pyrotinib to a neoadjuvant regimen of trastuzumab plus chemotherapy in patients with HER2-positive breast cancer who did not exhibit an early response to trastuzumab-based therapy alone. Here, ERBB2 is linked to breast carcinoma.